Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC125 Dose-Finding in Treatment-Experienced HIV-1
NCT00412646Phase 2Completed
- Sponsor
- Tibotec
- Start
- Jun 2002
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of etravirine in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Tibotec. Primary endpoint: Safety and tolerability of different doses of TMC125 at 48 weeks. Started Jun 2002; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00412646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412646.